Event

Transient receptor potential (TRP) channels have been studied as potential therapeutic targets for respiratory diseases in the last decade. The TRP channel family member, TRPV4 has been shown to be important in asthma, COPD, pulmonary edema, pulmonary HTN, ventilator-associated and acute lung injury, infection, and pulmonary fibrosis. TRPV4 channel therapeutic drugs are currently in preclinical/Phase I trials for pulmonary edema from heart failure. Hence, these agents may be applicable to treat other diseases. The goal of the session is to learn the biology of all TRP channels and specifically examine the physiology and therapeutic potential of TRPV4 in lung disease.